Huifeng Bio-Pharmaceutical Technology has successfully closed two million dollar convertible debt financing.
Subscribe to our email newsletter
The debt is convertible into shares of common stock at $1 per share and the company intends to use the proceeds to fund acquisitions of synergistic companies within the Shaanxi Province, China.
Primary Capital acted as the sole placement agent for this transaction.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.